242 related articles for article (PubMed ID: 21483235)
1. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis.
Chu XY; Hou XB; Song WA; Xue ZQ; Wang B; Zhang LB
Cancer Biol Ther; 2011 Jun; 11(12):995-1000. PubMed ID: 21483235
[TBL] [Abstract][Full Text] [Related]
2. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
3. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
4. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Significance of Tumor Marker Detection in Patients
with Advanced Squamous Cell Carcimoma of the Lung].
Liang P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
7. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic value of serum tumor markers in differentiating malignant from benign solitary pulmonary nodules].
Ni LF; Liu XM
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):707-10. PubMed ID: 25331391
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
10. Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination.
Wang WJ; Tao Z; Gu W; Sun LH
Asian Pac J Cancer Prev; 2013; 14(7):4369-71. PubMed ID: 23992005
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.
Xu L; Su Z; Xie B
J Clin Lab Anal; 2021 Sep; 35(9):e23912. PubMed ID: 34296781
[TBL] [Abstract][Full Text] [Related]
12. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
13. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
Yang-Chun F; Min F; Di Z; Yan-Chun H
Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
[TBL] [Abstract][Full Text] [Related]
15. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
[TBL] [Abstract][Full Text] [Related]
16. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
17. Elevated tumor markers in patients with pulmonary alveolar proteinosis.
Fang SC; Lu KH; Wang CY; Zhang HT; Zhang YM
Clin Chem Lab Med; 2013 Jul; 51(7):1493-8. PubMed ID: 23314555
[TBL] [Abstract][Full Text] [Related]
18. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer.
Wang H; Zhang X; Liu X; Liu K; Li Y; Xu H
J Cancer Res Ther; 2016; 12(1):355-8. PubMed ID: 27072263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
